SEKISUI Diagnostics announces that it has received the CE (Conformité Européenne) mark for the OSOM ® Ultra Plus Flu A&B test and has begun commercialization in Europe.  

The test uses traditional lateral flow technology with performance close to or better than the sensitivity of other reader-based tests without using an instrument. It is intended for the qualitative detection of influenza type A and type B nucleoprotein antigens directly from nasal or nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection.  

"The CE marking of the OSOM ® Ultra Plus Flu A&B test expands our influenza portfolio, allowing us to provide a more accurate rapid influenza test kit to many different institutions in more countries. WHO recognizes  that rapid influenza tests can have important implications for case management, specifically allowing the use of influenza antivirals.Other benefits may include isolation, grouping, and analysis of confirmed cases to help prevent outbreaks in the hospital setting and reduce inappropriate use of antibiotics, "said Robert Schruender, President and CEO of SEKISUI Diagnostics. "Accurate flu diagnosis is critical to controlling or ruling out flu and can help guide healthcare professionals when trying to diagnose other respiratory infections. This is especially important in our current situation where SARS-CoV testing -2 are not yet widely available. We are proud to be able to provide another diagnostic tool that can help protect patients and our communities. "  

SEKISUI Diagnostics offers solutions to meet diverse customer needs to help improve patient outcomes, maximize clinical efficiency, and reduce operating budgets. "Reflecting on last year's unprecedented respiratory season, we have seen the value of testing that can respond to high-volume clinical demand no matter where testing is done," said David Morris , PhD, director of product. " Rapid point-of-care testing remains an essential tool in the health system's ability to respond to increased demand for testing and reduce the spread of respiratory infections." 

Test patients provide clinicians with valuable information that enables treatment decisions and reduces the risk of prescribing unnecessary antivirals and antibiotics, or allows referrals for more extensive testing if necessary.  

About SEKISUI Diagnostics: 

SEKISUI Diagnostics is a global diagnostics company committed to improving the life of the patient by providing innovative medical diagnostics to physicians and laboratories through a global business network. Product lines include clinical chemistry and coagulation / reagent systems, rapid test kits and point of care systems, as well as specialty biochemicals and enzymes.  

 

Source: prnewswire.com

Report Abuse